Stockscreener 앱 받기
1.74
1.75%
0.03
Cel-Sci Corp. 주식(CVM)의 최신 뉴스
Cel-Sci Corporation (CVM) Jumps 11.98% to $2.71 as Buyers Push Toward ResistanceETF AUM Growth - https://www.siam.in/
Form 4 CEL-SCI Corp For: 1 October By Investing.com - Investing.com Australia
CEL SCI Corp CSO Eyal Talor Purchases 1,165 Shares of Common Stock - Kalkine Media
A 1,165-share award brings Eyal Talor’s direct CEL SCI CORP (CVM) holdings to 10,483 shares. - stocktitan.net
A 2,082-share award brings CEL SCI CORP (CVM) CFO Patricia B. Prichep's direct holding to 19,571 shares. - stocktitan.net
A 2,621-share grant leaves CEL SCI CORP (CVM) CEO holding 318,763 shares directly. - stocktitan.net
Cel-Sci Corporation (CVM) Stock Analysis: Unpacking The 738% Potential Upside - DirectorsTalk Interviews
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology - Investing News Network
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology - Yahoo Finance
CEL-SCI Corp (CVM) Key Financial Ratios – Valuation, Profitability & More - Value Research
Cel Sci CEO Geert Kersten purchases $138,000 in shares By Investing.com - Investing.com Nigeria
Cel Sci CEO Geert Kersten purchases $138,000 in shares By Investing.com - Investing.com South Africa
Cel Sci CEO Geert Kersten purchases $138,000 in shares By Investing.com - Investing.com UK
CEL SCI (CVM) CEO adds 100K restricted shares to his stake - Stock Titan
Cel-Sci (CVM) Outlook: Ends Up by 3.14% at $1.64 for the Current Session; Key Range: the Price Remains Bounded by the Supplied Support and Resistance at the CloseHagopian Line - vinanet.vn
CEL-SCI Company Profile & Introduction - Moomoo
CEL-SCI closes $2.5M offering to fund Multikine - scanx.trade
CEL-SCI Q3 Results: Per-share loss narrows 65% YoY to $(0.47) - scanx.trade
Cel-Sci shareholders elect directors and approve compensation plans at annual meeting - Investing.com
CEL SCI director granted 110K options at $1.49 | CVM Insider Trading - Stock Titan
CEL-SCI director granted 110K options at $1.49 | CVM Insider Trading - Stock Titan
CEL-SCI (NYSE: CVM) awards CEO 300,000 options over 3 years - Stock Titan
CEL-SCI (NYSE: CVM) awards Cipriano 80K options vesting over 3 years - Stock Titan
CEL-SCI (CVM) awards CSO Talor Eyal 250,000 stock options - Stock Titan
Form 8K CEL-SCI Corp For: 17 August By Investing.com - Investing.com Nigeria
CEL-SCI (NYSEAMERICAN: CVM) CFO lands new 2036 stock option grant - Stock Titan
Form 8K CEL-SCI Corp For: 17 August By Investing.com - Investing.com Canada
Form 8K CEL-SCI Corp For: 17 August By Investing.com - Investing.com India
Form 8K CEL-SCI Corp For: 17 August By Investing.com - Investing.com UK
CEL-SCI (CVM) Advances Multikine Trial Amid Low Valuation and Gu - GuruFocus
CEL-SCI Reports Fiscal Third Quarter 2026 Results - Yahoo Finance
CEL-SCI Reports Fiscal Third Quarter 2026 Results - Investing News Network
Cel-Sci: Fiscal Q3 Earnings Snapshot - marketscreener.com
Cel-Sci: Fiscal Q3 Earnings Snapshot - AOL.com
Cel-Sci: Fiscal Q3 Earnings Snapshot - cbs19news.com
Cel-Sci: Fiscal Q3 Earnings Snapshot - KTVB
CEL-SCI (CVM) faces going concern risk amid $16.6M loss and $6.5M cash - Stock Titan
CEL-SCI Corp (CVM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CEL-SCI Corp (CVM) Stock News Today - tradingkey.com
CEL-SCI publishes study on Multikine cancer treatment biomarkers - Investing.com
CEL-SCI (CVM) Advances Oral Cancer Immunotherapy Amid Challengin - GuruFocus
Before surgery, Multikine cut disease-progression risk 49% in study - Stock Titan
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study - Yahoo Finance
CEL-SCI Trial Reports 73% Five-Year Survival in Low PD-L1 Oral Cancer - Stock Titan
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients - Yahoo Finance
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients - Investing News Network
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients - Business Wire
CEL-SCI Corp (CVM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CEL-SCI Corp (CVM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CEL-SCI Corp (CVM) Institutional Confidence - TradingKey
1.35%
자본화:
|
볼륨(24시간):